Similar articles

• Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.

  Manganiello V. Manganiello V. Curr Opin Pharmacol. 2011 Dec;11(6):646-8. doi: 10.1016/j.coph.2011.10.016. Epub 2011 Nov 10. Curr Opin Pharmacol. 2011. PMID: 22079477 No abstract available.
• Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.

  Ko WC, Shih CM, Lai YH, Chen JH, Huang HL. Ko WC, et al. Biochem Pharmacol. 2004 Nov 15;68(10):2087-94. doi: 10.1016/j.bcp.2004.06.030. Biochem Pharmacol. 2004. PMID: 15476679
• [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].

  Medvedeva MV. Medvedeva MV. Biokhimiia. 1995 Mar;60(3):364-86. Biokhimiia. 1995. PMID: 7734612 Review. Russian.
• PDE inhibitors: a new approach to treat metabolic syndrome?

  Lugnier C. Lugnier C. Curr Opin Pharmacol. 2011 Dec;11(6):698-706. doi: 10.1016/j.coph.2011.09.012. Epub 2011 Oct 19. Curr Opin Pharmacol. 2011. PMID: 22018840 Review.
• Phosphodiesterase inhibitors.

  Boswell-Smith V, Spina D, Page CP. Boswell-Smith V, et al. Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S252-7. doi: 10.1038/sj.bjp.0706495. Br J Pharmacol. 2006. PMID: 16402111 Free PMC article. Review.